KASBP SAN FRANCISCO

KASBP 재미한인제약인협회

KASBP-SF SYMPOSIUM 2025

Scientific exchange, collaboration, and networking opportunities among professionals in biotech, pharma, academia, and government

JANUARY 11, 2025

Embassy Suites by Hilton San Francisco Airport
(250 Gateway Blvd, South San Francisco, CA 94080)

SYMPOSIUM SCHEDULE

8:30-9:00	Registration with light breakfast	Facilitator: OhKyu Yoon

Opening and Congratulatory Remarks

9:00-9:05	President, KASBP-SF	OhKyu Yoon
9:05-9:10	Consul General, San Francisco Embassy	Jung-Taek Lim

Session 1

Clinical and Translational Research — Chair: Jin-Hwan Han

9:10-9:45	A novel CD80/IL2v immunocytokine for cancer therapy	Nari Yun GI Innovation
9:45-10:20	Challenges in clinical development for a rare cancer A case of adenoid cystic carcinoma	Hyunseok Kang UCSF
10:20-10:35	Coffee Break	
10:35-11:10	4-1BB T cell engaging BsAb (Grabody T) activated T cells only in the tumor microenvironment and demonstrated superior efficacy and safety profile	Sang Hoon Lee ABL Bio

Sponsor Presentation I — Moderator: Agatha Lee

11:10-11:25	Yuhan	Lauren Young-Mi Lee
11:25-11:40	Gradiant Bioconvergence	Jinguen Rheey
11:40-11:55	Dong-A ST	Mi-Kyung Kim
11:55-12:05	Group Photo	Photographer: Siyeon Rhee
12:05-1:05	Lunch	Moderator: Sungjin Lee
1:05-2:25	Roundtable Networking	Moderator: Sungjin Lee

Sponsor Presentation II — Moderator: Hyang Jo

2:25-2:40	LigaChemBio	Jeiwook Chae
2:40-2:55	KEIT	Gi-Hwan Nam

Session 2

Advances and Innovations in Cell and Gene Therapy — Chair: Soojin Kim

2:55-3:30	Translational research in personalized cancer immuno therapy	Francis Sheen BioNTech
3:30-3:45	Coffee Break	
3:45-4:20	Advances in mRNA delivery platforms, SENS™: Enhancing therapeutic potential and selectivity for targeted delivery of mRNA	Helen Cho Samyang Holdings Corp.
4:20-4:55	Immune system specific delivery with hydrophilic nanoparticle	Kunwoo Lee GenEdit
4:55-5:00	Closing Remarks - KASBP-SF President	OhKyu Yoon
5:00-6:00	Social Networking	

Session 1

SPEAKERS

Nari Yun, Ph.D.

- Executive Managing Director, Head of Clinical/Strategy
  GI Innovation

Dr. Nari Yun is a head of clinical/strategy of GI Innovation, Inc, a science-driven biotechnology company located in Korea, focusing on cancer and allergic disease. She is now leading the clinical and business development of GI Innovation's pipeline. Dr. Yun began her career at Hanmi Pharmaceuticals, took the major role in clinical development programs for key assets including long-acting insulin, GLP-1 agonist and GLP-1/GCG dual agonist, contributing to licensing deal of those assets to Sanofi and Janssen. She also served as a strategic consultant in IQVIA (formerly known as IMS Consulting Group), delivering projects for key business decisions of pharma or biotech. Prior to joing to GI Innovation, she re-joined to Hanmi Pharmaceuticals as a clinical science leader and led the strategy development and clinical science of early-stage biologics. Dr. Yun is a registered pharmacist in Korea and was educated at School of Pharmacy, Sunkyunkwan University, where she received her PhD in pharmacology in 2012.

Abstract

A novel CD80/IL2v immunocytokine for cancer therapy

GI-102 (CD80-IL2v3) is a novel immunocytokine, designed to direct IL-2v to tumor and immune cells. IL-2v3 of GI-102 is designed to abolish the affinity to IL-2Rα thereby maximizing expansion of cytotoxic T and NK cells but not Treg cells. CD80 portion of GI-102 further inhibits Treg cell function. GI-102 delivers immunostimulatory payloads to tumor microenvironment, resulting in substantial broadening of therapeutic window of cytokine therapy. In first-in-human trial of GI-102, GI-102 showed great safety and tolerability, showing no dose-limiting toxicities up to highest dose injected (0.45 mg/kg).

Furthermore, it exerted strong monotherapy activity in different advanced or metastatic solid tumors previously failed on standard of care, including melanoma, bladder cancer, ovarian cancer, merkel cell carcinoma. The peripheral blood of patients received GI-102 showed strong expansion of total lymphocytes, CD8+ T and NK cells, but not Treg, resulting in favorable CD8+ T/Treg and NK/Treg ratio.

GI-102 is available for both intravenous and subcutaneous injection. It is currently at Phase 2, and being combined with different treatment modalities for cancer including trastzumab-deruxtecan (T-DXd, Enhertu®, AstraZeneca) and pembrolizumab (Keytruda®, MSD). In this talk, the recent progress on immunocytokine and key nonclinical and clinical data of GI-102 will be shared.

Hyunseok Kang, MD, MPH

- Professor, Division of Hematology/Oncology, Department of Medicine
  University of California, San Francisco
- Chair, Oral, Head and Neck Cancer Site Committee
  Helen Diller Family Comprehensive Cancer Center

Dr. Hyunseok "Hyu" Kang is a medical oncologist and clinician scientist specializing in head and neck cancers, including squamous cell carcinoma (SCCHN), salivary gland cancers, thyroid cancers, and other rare malignancies in this region. He leads the clinical research program for the Oral, Head, and Neck Cancer Program at UCSF, where he serves as an active clinical investigator. Dr. Kang has been the principal investigator for numerous investigator-initiated and industry-sponsored clinical trials and is a trusted advisor to pharmaceutical and biotech companies at various stages of development. Dr. Kang's research focuses on rare head and neck cancers, with a particular emphasis on adenoid cystic carcinoma, a disease with no currently approved standard of care. Prior to joining UCSF, he was an Assistant Professor of Oncology and Otolaryngology–Head and Neck Surgery at Johns Hopkins University School of Medicine in Baltimore, MD. Dr. Kang earned his medical and public health degrees from Yonsei University in Seoul, South Korea. He then completed his residency training at St. Luke's Roosevelt Hospital Center/Columbia University in New York City, followed by a fellowship in hematology and medical oncology at Emory University in Atlanta, GA.

Abstract

Developing Novel Therapies for Rare Cancers: A Case Study in Adenoid Cystic Carcinoma

Adenoid cystic carcinoma (ACC) is a rare salivary gland cancer, affecting approximately 5,000 new patients annually in the United States. While many patients initially undergo surgery with curative intent, a significant proportion eventually develop metastatic disease, for which no standard treatment options currently exist. Recent clinical trials have demonstrated limited efficacy of Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors such as lenvatinib, axitinib, and rivoceranib, underscoring the substantial unmet clinical need in this population. This presentation will explore the current landscape of therapeutic options for ACC, highlighting ongoing challenges and opportunities in drug development for this rare cancer. Using ACC as a case study, the talk will outline strategies for advancing novel therapies in the field of oncology, offering insights into the unique complexities of clinical trial design, regulatory pathways, and collaboration with industry partners to address rare diseases effectively.

Session 1

SPEAKERS

Sang Hoon Lee, Ph.D.

- CEO and Founder
  ABL Bio

Dr. Lee founded ABL Bio in February 2016 with the vision to build a company that offers patients a better life based on innovative science. Prior to ABL, Dr. Lee co-founded Pharm-Abcine where he oversaw all the research and development for antibody therapeutic projects. Before that, he was responsible for drug discovery and preclinical development as the Head of the Bio Division at Hanwha Chemical. Dr. Lee also brings years of experiences from global biopharmaceutical companies, including Chiron (Novartis), AstraZeneca, Genentech and Exelixis, where he gained cross functional knowledge in drug discovery, preclinical and clinical development of therapeutic antibodies. Dr. Lee received his Ph.D. in Molecular, Cellular and Developmental Biology at The Ohio State University and obtained his postdoctoral fellowship at the Harvard Medical School, UCSF and Stanford Medical School. He earned his M.S. in Developmental Biology and B.S. in Biology Education from Seoul National University.

Abstract

4-1BB T Cell Engaging BsAb (Grabody T) Activated T Cells only in the Tumor Microenvironment and Demonstrated Superior Efficacy and Safety Profile

Although CD137 (4-1BB) is a crucial receptor in T-cell-mediated immune functions, clinical development for therapeutic use has not been successful, specifically due to hepatotoxicity. Various efforts are currently underway to develop the next generation of bispecific antibodies that can harness the potent T-cell activation of 4-1BB with no risk of peripheral toxicity. Therefore, we designed the Grabody T bispecific antibody platform, which only activates T cells in the presence of TAA (Tumor Associated Antigen) within the tumor microenvironment. A novel anti-CD137 (4-1BB) antibody recognizing the membrane-proximal CD137 domain (CRD4) elicits potent anti-tumor T cell activity in a bispecific antibody format. Ragistomig (ABL503/TJ-L14B) is a bispecific antibody with full-length anti-PD-L1 mAb (Fc-silenced human IgG1) fused with scFv of an anti-4-1BB engaging mAb. It is designed to induce 4-1BB signaling only when bound to the PD-L1 tumor antigen on cancer cells, which may overcome resistance to PD-(L)1 inhibition and avoid hepatoxicity seen with multiple other 4-1BB-based antibodies. Preclinical studies have demonstrated that ABL503 shows better anti-tumor activity than single parental antibodies or in combination. The first-in-human Phase 1 study of ABL503 investigated doses ranging from 0.7 mg (flat dose) to 10 mg/kg (weight-based dose) IV every 2 weeks (Q2W) in patients with advanced or relapsed/refractory solid tumors, to assess the safety profile (primary endpoint) as well as preliminary anti-tumor effect and pharmacokinetic (PK)/pharmacodynamic (PD) profiles (secondary endpoints). In addition, a novel bispecific antibody targeting Claudin 18.2 (CLDN 18.2) and 4-1BB, termed ABL111 (ABL111/TJ-CD4B), is developed to elicit superior T cell activation through CLND 18.2 dependent 4-1BB clustering. Phase 1 monotherapy study of Givastomig, a Claudin 18.2x4-1BB bispecific antibody, demonstrated promising single-agent activity in heavily pre-treated patients with gastroesophageal carcinoma (GEC) expressing Claudin 18.2.

Session 2

SPEAKERS

Francis Sheen, Ph.D.

- Senior Scientist II
  BioNTech

Dr. Joong Hyuk Francis Sheen is a trained immunologist with global experiences in the biotech-pharma industry. Francis has been interested in deciphering mechanisms of disease states associated with inflammation ranging from organ transplantation to immuno-oncology. He is a Senior scientist II on the Translational Immunology team at the BioNTech US since 2020, leading establishment of biomarker and translational research strategies employing multidisciplinary approaches. He actively participates in academic organizations such as the American Association for Cancer Research (AACR) and Society for Immunotherapy of Cancer (SITC). He has been awarded the Young Investigator Awards at the American Transplant Congress (2015, 2016), the Achievement Fellowship Award at the Icahn School of Medicine at Mount Sinai (2017), and the Sonia Ting Award for Employee Excellence at BioNTech (2022). Prior to joining BioNTech, he was an investigator at the MOGAM Institute for Biomedical Research (currently GC Biopharma) in South Korea. He received a B.S. degree from the University of Washington and a Ph.D. degree in immunology from the Icahn School of Medicine at Mount Sinai.

Abstract

Translational research in personalized cancer immunotherapy

Studying the impact of cancer immunotherapies on the patients in the clinical trials and their underlying mechanisms of response and resistance are the key goals of implementing translational research strategies. In a phase 1 clinical study, a personalized neoantigen peptide vaccine, in combination with chemotherapy and PD-1 blockade, showed safety and immunogenicity and induced durable vaccine-specific T cell responses in patients with metastatic nonsquamous non-small-cell lung cancer. Multi-modal single-cell RNA-sequencing analysis further revealed thorough profiling of immune cells derived from the patient samples at the post treatment time point where neoantigen-specific T cells have an activated effector phenotype, as well as a cytotoxic gene signature. In a separate phase 1 study evaluating a personalized, autologous T cell therapy in patients with metastatic melanoma, similar translational approaches were utilized to document persistence of neoantigen-specific T cells and their phenotypes in the patient periphery and the tumor microenvironment. In conclusion, the translational analysis enables in-depth characterization of diverse patient samples across multiple indications, helping to elucidate immune responses specific to neoantigen.

Helen Cho, Ph.D.

- Head of Global R&D
  Samyang Holdings Corporation
- President
  Samyang Biopharm USA

Helen Cho, PhD is the Head of Global R&D of Samyang Holdings Corporation and President of Samyang Biopharm USA Inc. In 2024 Samyang celebrates a century of business growth and expansion in the sectors of Chemical, Packaging, Food and Biopharmaceutical. R&D of Biopharmaceutical division is strategically focused on products for medical surgical care, medical aesthetics, anti-cancer pharmaceuticals and delivery systems for nucleic acid therapeutics, positioning the company as a key player of healthcare industry. Prior to Samyang, Helen served as the program director for immuno-oncology programs as a member of the Vaccine and Immunotherapeutics Department at Pfizer Inc. She led multidisciplinary R&D programs from discovery, platform development, to early clinical advancement for developing drugs for oncology and CVMED diseases. She received her Ph.D. in molecular biology and biochemistry from the University of Medicine and Dentistry of New Jersey and completed her postdoctoral training at the Salk Institute for Biological Studies.

Abstract

Advances in mRNA delivery platforms, SENS™ (Stability Enhanced Nanoshell): Enhancing therapeutic potential and Selectivity for targeted delivery of mRNA

The field of mRNA therapeutics continues to evolve rapidly. Yet, there have been limitations of the use of LNP-mRNA in therapeutic areas where repeated dosing is required for chronic treatment. Samyang's SENS™ platform is the most advanced LNP-polymer delivery platform capable of selective delivery of mRNA to specific target tissues and cells with improved safety profile. Each tissue-selective SENS™ comprising proprietary ionizable lipid(s) and biodegradable polymer is optimized for delivery to a specific target tissue and cell type such as hepatocytes (Hepa-SENS), pulmonary endothelial cells (PEn-SENS), pulmonary epithelial cells (PEp-SENS), splenic dendritic cells (NanoReady) with superior efficiency in mice and NHPs. The structural properties of the ionizable lipid, combined with the diverse combinations of other key components provide unique physiochemical characteristics that overcome the limitations of conventional LNP delivery by effectively evading liver toxicity and neutralizing antibody production, even with repeat administration. SENS ™ platform possesses excellent efficacy and safety by enabling tissue-cell selective delivery of mRNA. The development of mRNA-based therapeutics using SENS™ for various diseases is currently underway with the aim of providing new and better treatment options for patient with intractable disease.

Session 2

SPEAKERS

Kunwoo Lee, Ph.D.

- CEO and Co-founder
  GenEdit

Dr. Kunwoo Lee is the CEO and Co-Founder of GenEdit. He is an innovator and believer of gene therapy. He is the inventor of several delivery technologies for gene therapy including CRISPR gene editing. Prior to GenEdit, he completed graduate research at UC Berkeley in the Department of Bioengineering. He was named as a Forbes 30 under 30 in 2017 and was a Siebel Scholar in 2016.

Abstract

Delivery of Genetic Medicine with Hydrophilic Nanoparticles

Conventional delivery technologies for genetic medicine face challenges: off-target delivery, innateimmune response, unable to repeat dose, or costly manufacturing. NanoGalaxy platform consists of a diverse library of hydrophilic polymers and, through systematic and iterative screening, has been used to identify nanoparticles with selective delivery to the innate immune system via intravenous administration. This presentation will introduce the NanoGalaxy platform and share the delivery results of genetic medicine payloads.

SPONSORS

GOLD

LigaChemBio

YUHAN

gradiant bioconvergence

DONG-A ST

SILVER

GI innovation

SAMYANG BIOPHARM USA

KEIT 한국산업기술기획평가원 Korea Planning & Evaluation Institute of Industrial Technology

BRONZE

Hanmi Global · R&D Leader Hanmi Pharm.

ablbio medicine for a better life

CUROCELL

GENEDIT

Consulate General of the Republic of Korea in San Francisco

ONEGENE BIOTECHNOLOGY

PharmAbcine Antibody Therapeutics for Life

MEPSGEN

COMMITTEE

President	윤오규 OhKyu Yoon	Gilead Sciences
President Team	김상엽 Sang Yeop Kim	Merck
Finance Team	조향 Hyang Jo	Genentech
	이동은 Agatha Lee	IFLI
Science Team	한진환 Jin-Hwan Han	Merck
	조효석 Hyosuk Cho	Sangamo Therapeutics
	김수진 Soojin Kim	Genentech
	이성진 Sungjin Lee	Surrozen
PR·Membership Team	장아람 Aram Chang	Bristol Myers Squibb
	황승용 Seung Yong Hwang	GRAIL
	이현철 Hyuncheol Lee	Stealth mode startup
	김기철 Kicheol Kim	Everest Detection
	박지원 Ji Won Park	Genentech
	김양준 Yang-Joon Kim	Chan Zuckerberg Biohub
Councilor	임한조 Hanjo Lim	Genentech
	정준원 Joon Won Jeong	Exelixis
	정가영 Claire Jeong	Genentech

Sign up for KASBP·SF membership on our website

www.kasbpsf.org

KASBP·SF membership is free.

Receive announcements on upcoming events

KASBP SAN FRANCISCO

KASBP-SF Symposium 2025 Attendees

Early Bird registrants only

	Last Name	First Name	이름	Company/Institution	Networking group
1	Bae	Eunchan	배은찬	AbbVie	2
2	Chae	Jeiwook	채제욱	LigaChem Biosciences	7
3	Chang	Kern	장건희	Lotte Biologics	6
4	Cho	Wansang	조완상	University	5
5	Cho	Yoojin	조유진	삼양홀딩스	5
6	Cho	Helen	조혜련	Samyang Holdings Corp.	5
7	Cho	Min-Kyu	조민듀	GSK	1
8	Cho	Yong	조용성	YC Consulting	3
9	Cho	Wooin	조우인	Stanford Cancer Institution	2
10	Cho	Hyosuk	조효석	Sangamo Therapeutics	5
11	Choi	Yongbin	최용빈	Simon-Kucher	6
12	Choi	Young Gi	최영기	Yuhan Corporation	1
13	Chun	Bokhwan	전복환	Korea Drug Development Fund (KDDF)	6
14	Chung	Seung Wook	정승욱	Johnson & Johnson	1
15	Chung	Alex	정관호	Sheppard Mullin	6
16	Fadeyi	Saudat		Samyang Biopharm USA Inc.	5
17	Gu	Sohyun	구소현	University of California, Berkeley	7
18	Han	Jin-Hwan	한진환	Merck & Co	5
19	Han	June HJ.	한혜정	Pharos Therapeutics Inc.	5
20	Her	Nam-Gu	허남구	Aimed Bio Inc.	6
21	Hong	Nan Hyung	홍난형	ESSA Pharma	1
22	Hur	Seong Kwon	허성권	Genentech Inc.	1
23	Hwang	Jurie	황주리	Organization	6
24	Hwang	Francis	황의성	Illumina	4
25	Hwang	Sungyong	황성용	Silver Spring, MD	3
26	Hwang	Hyun Tae	황현태	Truebinding	1
27	Im	Eunju	임은주	Amyloid Solution Inc	6
28	Im	San-Hae	임산해	UCSF	5
29	Jahng	Won Suk	장원석	Stanford University	7
30	JANG	MYUNGHO	장명호	GI Innovation	6
31	Jeong	Dae Young	정대영	LigaChem Biosciences	7
32	Jo	Hyang	조향	Genentech	6
33	Jo	Suji	조수지	Hanmi Pharmaceutical	6
34	Jung	Sungwon	정성원	UCSF Chemistry and Chemical Biology	1
35	Jung	Inyoung	정인영	Synthekine	1
36	Kang	Aram	강아람	Arsenal Bio	4
37	Kang	Yeonjoo	강연주	Fortrea	6
38	Kang	Jongkyun	강종균	Dong-A ST	5
39	Kim	Chae Eun	김채은	LigaChem Biosciences	6
40	Kim	Mi-Kyung	김미경	Dong-A ST Co., Ltd.	1
41	Kim	Yang Joon	김양준	Chan Zuckerberg Biohub, SF	4
42	Kim	jeewon	김지원	Stanford	6
43	Kim	Gyuhyeon	김규현	Stanford	4
44	Kim	Sang	김상엽	Merck	1
45	Kim	Sean	김성일	Samyang Biopharm USA Inc.	5
46	Kim	Ellen Jooyeon	김주연	Korea Drug Development Fund (KDDF)	6
47	Kim	Bonnie	김보연	Tempus AI	2
48	Kim	JaeB	김재범	Gilead Sciences	6
49	Kim	Kyung	김경효	AbbVie	3
50	Kim	Youngmi	김영미	Pfizer	6
51	Kim	Jongbin	김종빈	UCSF	1
52	Kim	Byungchan	김병찬	NeuroLambda Therapeutics	6
53	Kim	Soojin	김수진	Gilead Sciences	1
54	Kim	Hanyoup	김한엽	10X Genomics	5
55	KIM	YU-MEE	김유미	Genentech	2
56	Kim	Sunmi	김선미	ICI	1
57	Kim	Soojin	김수진	Genentech	5
58	Ko	Donggun	고동건	Fresenius-Kabi, USA	3
59	Koh	Jae Chul	고재철	Korea University College of Medicine	6
60	KOH	YOUNGJUN	고영준	GI Innovation	2
61	Kwon	Ji	권지현	Genentech	6
62	Lee		이윤경	stanford medicine	7
63	Lee	Jeehee	이지희	Stanford	1
64	Lee	Kunwoo	이근우	GenEdit	5
65	Lee	Sang Hoon	이상훈	에이비엘바이오 (ABL Bio)	6
66	Lee	Hyuncheol	이현철	Vivere Oncotherapies	3
67	Lee	Ha Young	이하영	Mepsgen	5
68	Lee	Narae	이나래	Arcturus Therapeutics	3
69	Lee	Jae Yun	이재윤	Analysis	6
70	Lee	TaeWeon	이태원	Wincal Biopharm, Inc.	6
71	Lee	Jisoo	이지수	Safeway Pharmacy	2
72	Lee	Anthony	이재용	Immunome, Inc.	2
73	Lee	Lauren Youngmi	이영미	Yuhan Corporation	6
74	Lee	Hong-Pyo	이홍표	MEDIC LIFE SCIENCES	6
75	Lee	Sungjin	이성진	Surrozen	1
76	Lee	Grace	이호영	Elevalue Consulting	5
77	Myoung	Sunghyun	명성현	Bridgene Biosciences	1
78	Nam	Heejae	남희재	University of California, Berkeley	2
79	Oh	Minyoung	오민영	UC Berkeley - UCSF	3

KASBP-SF Symposium 2025 Attendees

Early Bird registrants only

80	Oh	Hyejin	오혜진	Dong-A ST USA	6
81	Park	Sungjin	박성진	ONEGENE BIOTECHNOLOGY	1
82	Park	Sejin	박세진	LigaChem Biosciences	7
83	Park	Ji Won	박지원	Genentech	4
84	Park	Jinho	박진호	Seawolf Therapeutics	5
85	Park	Hyeri	박혜리	Kimia Therapeutics	1
86	RHEE	BYUNGGEON	이병건	GI Innovation	6
87	Rheey	Jinguen	이진근	Gradiant Bioconvergence	1
88	SEO	HYEONGYU	서현규	ONEGENE BIOTECHNOLOGY	1
89	Sheen	Francis	신중혁	BioNTech US	1
90	Shim	Eunha	심은하	Gradiant Bioconvergence	1
91	Shim	Jeongsup	심정섭	GENENTECH	2
92	Sim	Peter	심주엽	PharmAbcine Inc.	6
93	Song	Kyung Han	송경한	BI	3
94	Song	Jihong	송지홍	UCSF	2
95	Suh	Chris		Biotage	1
96	Woo	Sangsoon	우상순	Corcept Therapeutics	2
97	Yoo	Jin-San	유진산	PharmAbcine Inc.	6
98	Yoon	Taejin	윤태진	Yuhan Corporation	6
99	Yoon	OhKyu	윤오규	Gilead Sciences	2
100	Yu	Seungyoon	유승윤	Denali Therapeutics	1

■ Networking Groups (2025 KASBP-SF Symposium)

	Networking group
1	Discovery - Early Development of Therapeutics
2	Translational & Clinical Research, Biomarker
3	CMC, Manufacturing, & Late Development of Therapeutics / Regulatory Affairs
4	AI / ML, Bioinformatics, Statistics
5	Platforms & Enabling Technologies
6	Business Development, Venture Capital, Corporate Development
7	Career Development

Venue Map



NOTES

NOTES

KASBP
재미한인제약인협회

KASBP
SAN FRANCISCO

Contact Us
KASBP San Francisco

www.kasbpsf.org